2026. Reduction in Pruritus Across Indications in Phase 3 Trials of Topical Roflumilast in Patients as Young as 2 Years. SKIN The Journal of Cutaneous Medicine. 10, 2 (Mar. 2026), s766. DOI:https://doi.org/10.25251/94s3pn30.